Gibson Dunn Advised Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

Gibson Dunn Advised Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

Gibson Dunn advised Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings.

The Gibson Dunn corporate team includes Ryan Murr (Partner), Melanie Neary (Partner) and Branden Berns (Partner) and Evan Shepherd (Associate) and Candice Johnson (Associate).

Click to know more about Gibson Dunn

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.